- Home
- LUCD vs UNCY Comparison
LUCD vs UNCY Comparison
Compare LUCD & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | UNCY |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.9M | 141.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LUCD | UNCY |
|---|---|---|
| Price | $1.40 | $6.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $3.94 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 780.1K | 480.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.67 | ★ 56.25 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,346,000.00 | $675,000.00 |
| Revenue This Year | $7.69 | N/A |
| Revenue Next Year | $155.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.95 | $0.45 |
| 52 Week High | $1.80 | $7.57 |
Technical Indicators
Market Signals| Indicator | LUCD | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 57.65 | 49.86 |
| Support Level | $1.01 | $5.90 |
| Resistance Level | $1.52 | $6.82 |
| Average True Range (ATR) | 0.08 | 0.36 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 56.52 | 41.59 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.